Publication: Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study
1
Issued Date
2019-02-17
Resource Type
ISSN
15210669
08880018
08880018
Other identifier(s)
2-s2.0-85064524246
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatric Hematology and Oncology. Vol.36, No.2 (2019), 73-81
Suggested Citation
Jassada Buaboonnam, Nattee Narkbunnam, Nassawee Vathana, Chayamon Takpradit, Kamon Phuakpet, Bunchoo Pongtanakul, Sasima Tongsai, La Ongsri Atchaneeyasakul, Kleebsabai Sanpakit Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study. Pediatric Hematology and Oncology. Vol.36, No.2 (2019), 73-81. doi:10.1080/08880018.2019.1600083 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/51857
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study
Other Contributor(s)
Abstract
© 2019, © 2019 Taylor & Francis Group, LLC. Retinoblastoma is the most common intraocular malignancy in children. The aim of this study was to investigate the efficacy and toxicity of combination ifosfamide, carboplatin, etoposide, and vincristine (ICEV) in advanced-stage pediatric retinoblastoma [International Classification of Retinoblastoma (ICRB) group D or E], and in ICRB group C in the second eye in simultaneously treated bilateral retinoblastoma. The medical records of retinoblastoma patients treated with concurrent ICEV regimen and focal therapy were retrospectively reviewed. The ICEV treatment protocol was, as follows: ifosfamide 1800 mg/m2 on Days 1–3; MESNA 600 mg/m2 on Days 1–3; carboplatin 560 mg/m2 on Day 1; etoposide 150 mg/m2 on Days 1–3; and vincristine 1.5 mg/m2 on Day 1. Of 16 retinoblastoma patients, 13 had bilateral disease. Seven first eyes in bilateral disease that were enucleated prior to ICEV therapy were excluded. Twenty-two eyes were finally included (six group C, six group D, and ten group E). Median follow-up was 3.4 years, and the median number of ICEV courses was 7. Fifteen globes could be salvaged, 12 responded to ICEV (six group C, five group D, and one group E), and three unresponsive eyes could be salvaged with external beam radiation therapy (EBRT). Enucleation-free and relapse-free survival was 68.2 and 54.5%, respectively. The results of this study suggest ICEV as an alternative therapeutic approach for globe salvage in pediatric retinoblastoma, especially in ICRB groups C and D with manageable acute toxicity. Further study in larger cohort is needed to confirm the effectiveness of treatment.